Accessible Search Form           Advanced Search

9. Research Grants


NHLBI Research Grants by Funding Mechanism:  Fiscal Year 2007

 

Number of
Grants

Total Cost
(Dollars in Thousands)

Percent of
Total NHLBI
Research
Grant Dollars

Research Project Grants (RPGs)

 

 

 

Research Project Grants (Excluding Small Business RPGs)

 

 

 

Regular Research Grants (R01)

3,121

$1,294,558

57.21%

Program Project Grants (P01)

169

340,031

15.03

Cooperative Agreements (U01)

226

200,402

8.86

Area Grants (R15)

18

3,881

0.17

Explorative Developmental Grant (R21)

151

30,532

1.35

Exploratory/Developmental Grants Phase II (R33)

22

6,949

0.31

Method to Extend Research in Time (R37)

77

32,199

1.42

NIH Director's Pioneer Award (DP2)

1

2,625

0.12

Cooperative Agreements (U19)

1

2,000

0.09

Subtotal, Research Project Grants (Excluding Small Business RPGs)

3,786

1,913,177

84.54

Small Business Research Project Grants

 

 

 

Small Business Technology Transfer (STTR Phase I) (R41)

9

1,606

0.07

Small Business Technology Transfer (STTR Phase II) (R42)

16

6,983

0.31

Small Business Innovation Research (SBIR Phase I) (R43)

59

9,950

0.44

Small Business Innovation Research (SBIR Phase II) (R44)

90

54,976

2.43

Subtotal, Small Business Research Project Grants

174

73,515

3.25

Subtotal, Research Project Grants

3,960

1,986,692

87.80

Research Center Grants

 

 

 

Specialized Centers of Research (SCOR) (P50)

39

104,961

4.64

Sickle Cell Centers (U54)

11

23,559

1.04

Center for AIDS Research (P30)

3,571

0.16

Specialized Centers (Cooperative Agreements) (U54)

5

8,523

0.38

National Swine Research and Resource Center (U42)

420

0.02

Subtotal, Research Center Grants

55

141,034

6.23

Research Career Programs

 

 

 

Mentored Research Development Award for Minority Faculty (K01)

35

4,718

0.21

Minority Institution Faculty Mentored Research Scientist Award (K01)

5

698

0.03

Mentored Scientist Development Award in Research Ethics (K01)

3

357

0.02

Independent Scientist Award (K02)

25

2,511

0.11

Pediatric Transfusion Medicine Academic Award (K07)

4

486

0.02

Cultural Competence and Health Disparities Academic Award (K07)

18

2,232

0.10

Clinical Investigator Scientist Award (K08)

214

27,286

1.21

Vascular Medicine Research Career Development Program (K12)

7

3,206

0.14

Clinical Hematology Research Career Development Program (K12)

6

2,367

0.10

Genetics and Genomics of Lung Disease Career Development Program (K12)

8

3,154

0.14

Career Enhancement Award for Stem Cell Research (K18)

4

652

0.03

Mentored Patient-Oriented Research Career Development Award (K23)

120

16,419

0.73

Midcareer Investigator Award in Patient-Oriented Research (K24)

29

4,037

0.18

Mentored Quantitative Research Career Development Award (K25)

15

2,077

0.09

Clinical Research Curriculum Award (K30)

16

2,520

0.11

Career Transition Award (K22)

1

160

0.01

Career Transition Award (K99)

24

2,074

0.09

Subtotal, Research Career Programs

534

74,954

3.32

Other Research Grants

 

 

 

Cooperative Clinical Research (U10, R10)

48

36,622

1.62

Minority Biomedical Research Support (S06, R25, SC2)

3

2,474

0.11

Other (R09, R13, R18, R24, R25, T15, U09, U24, UH1)

100

21,234

0.94

Subtotal, Other Research Grants

151

60,330

2.67

Total, NHLBI Research Grants

4,700

$2,263,010

100%

NHLBI Total Research Grants by Category

Grants by Category
Text-only with data points

NHLBI Research Project Grant,* Research Centers Grant, and Other Research Grant Obligations:  Fiscal Years 1997–2007

NHLBI Research Project Grant,* Research Centers Grant, and Other Research Grant Obligations
Text-only with data points are represented in the table below.

*   Includes R01, U01, P01, R03, R15, R21, R29, R37, R41, R42, R43, and R44; R33 beginning in 2001; and DP2 and U19 in 2007.
** Includes Research Career Programs; excludes General Research Support Grants.

NHLBI Research Project Grants,* Research Centers Grants, and Other Research Grant Obligations:  Fiscal Years 1997–2007

Dollars (Thousands)

 

FY 1997

FY 1998

FY 1999

FY 2000

FY 2001

FY 2002

FY 2003

FY 2004

FY 2005

FY 2006

FY 2007

Research Project Grants*

$   935,322

$1,009,152

$1,142,473

$1,356,034

$1,580,751

$1,779,573

$1,920,201

$2,003,769

$2,042,050

$2,011,049

$1,986,692

Research Centers Grants

108,665

114,397

119,889

123,803

127,232

128,161

138,941

140,600

151,495

141,086

141,034

Other Research Grants**

56,993

66,234

84,219

90,666

88,958

98,460

113,172

112,785

116,713

123,802

135,284

Total

$1,100,980

$1,189,783

$1,346,581

$1,570,503

$1,796,941

$2,006,194

$2,172,314

$2,257,154

$2,310,258

$2,275,937

$2,263,010

*   Includes R01, U01, P01, R03, R15, R21, R29, R37, R41, R42, R43, and R44; R33 beginning in 2001; and DP2 and U19 in 2007.
** Includes Research Career Programs; excludes General Research Support Grants.

NHLBI Competing Research Project Grant Applications:*   Fiscal Years 1997–2007

Number Reviewed and Awarded

NHLBI Competing Research Project Grant Applications*:  Fiscal Years 1996-2006
Text-only with data points are represented in the table below.

Number Reviewed and Awarded and Percent Funded

 

FY 1997

FY 1998

FY 1999

FY 2000

FY 2001

FY 2002

FY 2003

FY 2004

FY 2005

FY 2006

FY 2007

Applications Reviewed

2,771

2,657

2,704

2,893

2,895

3,064

3,098

3,548

3,865

4,412

4,504

RPGs Awarded

821

837

959

1,003

1,033

1,018

1,064

1,034

909

871

943

Success Rate (percent)

29.6

31.5

35.5

34.7

35.7

33.2

34.3

29.1

23.5

19.7

20.9

*   Includes R01, U01, P01, R03, R15, R21, R29, and R37; R33 beginning in 2001; and DP2 and U19 beginning in 2007.

Percent of Reviewed Applications Funded (Success Rate)

NHLBI Competing Research Project Grant Applications*:  Fiscal Years 1996-2006
Text-only with data points are represented in the table above.

NHLBI Investigator-Initiated and Institute-Initiated Grant Obligations:  Fiscal Years 1997–2007

NHLBI Investigator-Initiated and Institute-Initiated Grant Obligations:  Fiscal Years 1996-2006
Text-only with data points are represented in the table below.

*   Includes RPGs, SBIRs/STTRs, Research Career Programs, and Other Research.
** Includes RPGs, Centers Grants, Research Career Programs, Other Research, and Cooperative Agreement RFAs.

NHLBI Investigator-Initiated and Institute-Initiated Grant Obligations:  Fiscal Years 1997–2007

Dollars (Millions)

 

FY 1997

FY 1998

FY 1999

FY 2000

FY 2001

FY 2002

FY 2003

FY 2004

FY 2005

FY 2006

FY 2007

Investigator-Initiated*

$  867.9

$   966.6

$1,069.9

$1,241.6

$1,446.2

$1,584.9

$1,681.9

$1,773.4

$1,822.9

$1,802.1

$1,774.8

Institute-Initiated**

233.0

223.2

276.7

328.9

350.7

421.3

490.4

483.8

487.3

473.8

488.2

Total

$1,100.9

$1,189.8

$1,346.6

$1,570.5

$1,796.9

$2,006.2

$2,172.3

$2,257.2

$2,310.2

$2,275.9

$2,263.0

*   Includes RPGs, SBIRs/STTRs, Research Career Programs, and Other Research.
** Includes RPGs, Centers Grants, Research Career Programs, Other Research, and Cooperative Agreement RFAs.

NHLBI Research Project Grants:*  Amount Funded by Type of Award, Fiscal Years 1997–2007

Dollars (Millions)

 

FY 1997

FY 1998

FY 1999

FY 2000

FY 2001

FY 2002

FY 2003

FY 2004

FY 2005

FY 2006

FY 2007

Competing

 

 

 

 

 

 

 

 

 

 

 

  New Competing

$135.8

$147.5

$   202.0

$   266.4

$   280.0

$   291.2

$   285.5

$   290.5

$   270.0

$   242.9

$   330.9

  Renewal Competing

104

103.9

127.2

152

143.9

143.9

177.2

185.5

176.1

168.3

169.4

  Competing Supplements

0.3

1

1.2

0.9

0.4

2.3

1

1.3

1.7

0.4

Subtotal, Competing

240.1

252.4

330.4

419.3

424.3

437.4

463.7

477.3

447.8

411.6

500.3

Noncompeting

 

 

 

 

 

 

 

 

 

 

 

Subtotal, Noncompeting

662.4

721.3

770.6

889.3

1,101.5

1,281.3

1,390.3

1,454.9

1,520.0

1,527.0

1,486.4

Total, Competing and Noncompeting

$902.5

$973.7

$1,101.0

$1,308.6

$1,525.8

$1,718.7

$1,854.0

$1,932.2

$1,967.8

$1,938.6

$1,986.7

*   Includes R01, U01, P01, R03, R15, R21, R29, R37, R41, R42, R43, and R44; R33 beginning in 2001; and DP2 and U19 beginning in 2007.

Facility and Administrative (F&A) Costs of NHLBI Research Project Grants:* Fiscal Years 1997–2007

Dollars (Thousands)

Fiscal Year

Direct Cost

F&A Cost

Total Cost

F&A Cost as a
Percent of Direct Cost

1997

$  611,576

$290,915

$  902,491

47.6%

1998

660,009

313,765

973,774

47.5

1999

764,198

336,756**

1,100,954

44.1

2000

891,244

417,312

1,308,556

46.8

2001

1,045,144

480,673

1,525,817

46.0

2002

1,182,408

536,324

1,718,732

45.4

2003

1,276,819

577,131

1,853,950

45.2

2004

1,329,106

603,133

1,932,239

45.4

2005

1,355,803

612,007

1,967,810

45.1

2006

1,334,406

604,183

1,938,589

45.3

2007

1,378,134

608,558

1,986,692

44.2

*   Includes R01, U01, P01, R03, R15, R21, R29, R37, R41, R42, R43, and R44; R33 beginning in 2001; and DP2 and U19 beginning in 2007.
** Excludes Program Evaluation Assessment of $1,216,000.

NHLBI Research Project Grants:*  Average Costs, Fiscal Years 1997–2007

NHLBI Research Project Grants*:  Average Costs, Fiscal Years 1996-2006
Text-only with data points are represented in the table below.

*   Includes R01, U01, P01, R03, R15, R21, R29, R37, R41, R42, R43, and R44; R33 beginning in 2001; and DP2 and U19 beginning in 2007.

NHLBI Research Project Grants:*  Average Costs, Fiscal Years 1997–2007

Dollars (Thousands)

 

FY 1997

FY 1998

FY 1999

FY 2000

FY 2001

FY 2002

FY 2003

FY 2004

FY 2005

FY 2006

FY 2007

Noncompeting

$323.0

$322.6

$323.4

$346.6

$390.7

$418.8

$444.4

$458.7

$490.6

$503.9

$510.3

Competing

292.5

301.6

344.5

418.0

410.8

409.1

406.7

419.7

459.9

458.1

477.8

Total

$314.2

$316.9

$329.4

$366.6

$396.1

$416.2

$433.8

$447.9

$484.8

$492.8

$501.7

*   Includes R01, U01, P01, R03, R15, R21, R29, R37, R41, R42, R43, and R44; R33 beginning in 2001; and DP2 and U19 beginning in 2007.

NHLBI Cooperative Agreements (U01, U10) Programs

Cooperative Agreements were instituted to support discrete, circumscribed projects in areas of an investigator’s spe­cific interest and competency with substantial programmatic participation by the NHLBI during performance of the activity.

 

Total Obligations
Prior to FY 2007

Total FY 2007
Obligations

Total Obligations
to Date

Heart and Vascular Diseases

 

 

 

AIM HIGH:  Niacin Plus Statin to Prevent Vascular Events

$    6,987,287

$    6,018,096

$    13,005,383

Atherosclerosis, Plaque, and CVD in Communities

13,259,110

2,885,489

16,144,599

Bypass Angioplasty Revascularization Investigation in Type 2 Diabetics (BARI 2D)

52,450,028

2,646,947

55,096,975

Cardiovascular Cell Therapy Research Network

4,424,183

4,424,183

Cardiovascular Heart Study (CHS) Events Follow-up Study

2,062,679

1,145,576

3,208,255

Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)

14,837,498

3,306,675

18,144,173

Claudication Exercise vs. Edoluminal Revascularization

2,846,994

1,898,415

4,745,409

Clinical Research Consortium To Improve Resuscitation Outcomes

25,408,658

8,971,584

34,380,242

Community-Responsive Intervention To Reduce Cardiovascular Risk in American Indians and Alaska Natives

1,418,746

2,314,003

3,732,749

Design and Analysis of Genome-Wide Association Studies

1,780,137

1,758,776

3,538,913

Dynamic Evaluation of Percutaneous Coronary Intervention

6,180,419

6,180,419

Family Blood Pressure Program

93,226,792

3,716,949

96,943,741

Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN)

11,838,340

2,029,384

13,867,724

Girls Health Enrichment Multisite Studies (GEMS)

19,418,195

19,418,195

Heart Failure:  A Controlled Trial Investigating Outcomes of Exercise Training (HF–ACTION)

34,118,122

2,846,477

36,964,599

Heart Failure Clinical Research Network

5,642,461

7,800,582

13,443,043

Home Automatic External Defibrillator Trial (HAT)

17,178,972

17,178,972

IMMEDIATE Trial:  Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care

25,650,639

25,650,639

Improved Measures of Diet and Physical Activity for the Genes and Environment Initiative

2,632,681

2,632,681

Network for Cardiothoracic Surgical Investigation in Cardiovascular Medicine

6,008,848

6,008,848

NHLBI Clinical Proteomics Program

10,024,329

4,920,952

14,945,281

Occluded Artery Trial (OAT)

17,224,514

1,452,378

18,676,892

Partnership Programs for Reducing Cardiovascular Health Disparities

20,929,126

7,330,477

28,259,603

Pediatric Heart Network

29,578,646

6,607,550

36,186,196

Pharmacogenetics Research Network

48,524,584

8,770,916

57,295,500

Preventing Overweight Using Novel Dietary Strategies (POUNDS LOST)

6,779,823

6,779,823

Programs in Gene by Environment Interaction (PROGENI)

46,713,444

1,459,246

48,172,690

Programs of Excellence in Nanotechnology

17,553,560

10,992,900

28,546,460

Programs of Genomic Applications (PGAs) for Heart, Lung, and Blood Diseases

195,107,611

14,039,424

209,147,035

Stop Atherosclerosis in Native Diabetics Study (SANDS)

11,079,036

197,305

11,276,341

Strong Heart Study

57,974,143

6,182,306

64,156,449

Surgical Treatment for Ischemic Heart Failure (STICH)

25,529,882

8,912,357

34,442,239

Trial of Activity for Adolescent Girls (TAAG)

34,211,102

34,211,102

Weight Loss in Obese Adults with Cardiovascular Risk Factors:  Clinical Interventions

2,567,146

3,713,946

2,567,146

Weight Loss Maintenance (WLM)

15,168,042

2,150,858

17,318,900

Subtotal, Heart and Vascular Diseases

873,270,065

137,135,280

1,006,691,399

Lung Diseases

 

 

 

Apnea Positive Pressure Long-Term Efficacy Study (APPLES)

12,542,181

1,532,037

14,074,218

Asthma Clinical Research Network (ACRN), Phase II

33,110,894

8,917,879

42,028,773

Centers for Reducing Asthma Disparities

27,350,819

27,350,819

Childhood Asthma Management Program–Continuation Study (CAMP-CS)/Phase III

2,077,278

2,077,278

Childhood Asthma Research and Education (CARE) Network

42,837,293

5,915,840

48,753,133

Clinical Trial of Acid Reflux Therapy in Asthma

3,083,552

662,283

3,745,835

Collaborative Programs in Bronchopulmonary Dysplasia

36,731,072

2,526,747

39,257,819

COPD Clinical Research Network

29,793,928

6,836,458

36,630,386

Early Antipseudomonal Therapy in Cystic Fibrosis

3,145,273

923,625

4,068,898

Genetic Epidemiology of COPD

6,113,536

6,113,536

Idiopathic Pulmonary Fibrosis Clinical Research Network

10,835,422

7,216,255

18,051,677

Pharmacogenetics of Asthma Treatment

17,494,738

3,190,981

20,685,719

Prospective Investigation of Pulmonary Embolism Diagnosis-III (PIOPED III)

6,643,681

1,518,303

8,161,984

Randomized Controlled Study of Adenotonsillectomy for Childhood Sleep Apnea

2,267,140

2,387,691

4,654,831

Sleep Heart Health Study

20,511,241

625,846

21,137,087

Study of Acid Reflux Therapy for Children with Asthma

774,454

846,333

1,620,787

Subtotal, Lung Diseases

247,121,688

51,291,092

298,412,780

Blood Diseases and Resources

 

 

 

Blood and Marrow Transplant Clinical Research Network

36,486,721

6,708,880

43,195,601

Center for Human Cell Therapy

7,281,374

2,096,324

9,377,698

Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair (FOCUS)

8,804,219

1,974,477

10,778,696

Sickle Cell Clinical Research Network

3,761,385

7,497,847

11,259,232

Stroke with Transfusions Changing to Hydroxyurea (SWITCH)

7,277,340

3,531,426

10,808,766

Thalassemia (Cooley’s Anemia) Clinical Research Network

16,787,170

2,618,369

19,405,539

Transfusion Medicine/Hemostasis Clinical Research Network

31,128,254

6,407,000

37,535,254

Subtotal, Blood Diseases and Resources

111,526,463

30,834,323

142,360,786

Total, NHLBI Cooperative Agreements

$1,231,918,216

$219,260,695

$1,447,464,965

Heart and Vascular Diseases Program

AIM HIGH: Niacin Plus Statin To Prevent Vascular Events, Initiated in Fiscal Year 2005

The purpose of this multicenter clinical trial is to determine whether extended-release niacin plus simvastatin is superior to simvastatin alone for preventing or delaying a major CVD event in patients with atherogenic dyslipidemia. Niacin is used to raise HDL (“good”) cholesterol and simvastatin is used to lower LDL (“bad”) cholesterol. Twenty-seven percent of the population will be from minority populations.

Obligations

Funding History:
Fiscal Year 2007—$6,018,096
Fiscal Years 2005–2006— $6,987,287
Total Funding to Date—$13,005,383

Current Active Organizations and Grant Numbers

  1. University of Washington
    Seattle, Washington —HL-081616
  2. AXIO Research, LLC
    Seattle, Washington —HL-081649

Atherosclerosis, Plaque, and CVD in Communities, Initiated in Fiscal Year 2004

The purpose of this study is to identify correlates of atherosclerotic plaque characteristics and early changes in the vascular wall in a subset of the biethnic Atherosclerosis Risk in Communities (ARIC) cohort. Investigators will use stored DNA samples to test genomic correlates of plaque characteristics and their ability to predict CHD and stroke.

Obligations

Funding History:
Fiscal Year 2007—$2,885,489
Fiscal Years 2004–2006—$13,259,110
Total Funding to Date—$16,144,599

Current Active Organization and Grant Number

  1. University of Texas Health Science Center
    Houston, Texas—HL-075572

Bypass Angioplasty Revascularization Investigation in Type 2 Diabetics (BARI 2D), Initiated in Fiscal Year 2000

The purpose of this trial is to compare alternative treatment strategies for managing patients with type 2 diabetes with angiographically proven coronary artery disease and stable angina or ischemia. Revascularization combined with aggressive medical anti-ischemia treatment will be compared to aggressive medical anti-ischemia treatment alone; simultaneously, researchers will determine whether insulin-sensitizing drugs such as metformin and the glitazones for controlling blood sugar level offer any survival advantage over drugs that increase insulin level. Twenty-one percent of the patients are from minority populations.

Obligations

Funding History:
Fiscal Year 2007—$2,646,947
Fiscal Years 2000–2006—$52,450,028
Total Funding to Date—$55,096,975

Current Active Organizations and Grant Numbers

  1. University of Pittsburgh
    Pittsburgh, Pennsylvania—HL-061744
  2. St. Louis University
    St. Louis, Missouri —HL-061746
  3. Stanford University
    Stanford, California —HL-061748
  4. University of Vermont
    Burlington, Vermont —HL-063804

Cardiovascular Cell Therapy Research Network, Initiated in Fiscal Year 2007

See Chapter 11. Clinical Trials.

Cardiovascular Heart Study (CHS) Events Follow-Up Study, Initiated in Fiscal Year 2005

The purpose of this project is to continue follow-up of the CHS cohort for cardiovascular events in order to enhance power among subgroups to study associations of CVD risk factors and incidence and prognosis following CVD events in older adults. The additional events will permit greater opportunity to address the study aims by CHS investigators and other researchers interested in making use of the study's extensive database and specimens. Seventeen percent of the participants are from minority populations.

Obligations

Funding History:
Fiscal Year 2007—$1,145,576
Fiscal Years 2005–2006—$2,062,679
Total Funding to Date—$3,208,255

Current Active Organization and Grant Number

  1. University of Washington
    Seattle, Washington —HL-080295

Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL), Initiated in Fiscal Year 2004

The purpose of this trial is to determine whether revascularization of a stenotic renal artery plus medical therapy is associated with improved clinical outcomes compared with medical therapy alone. Twenty-three percent of the participants will be from minority populations.

Obligations

Funding History:
Fiscal Year 2007—$3,306,675
Fiscal Years 2004–2006—$14,837,498
Total Funding to Date—$18,144,173

Current Active Organizations and Grant Numbers

  1. University of Toledo Health
    Sciences Campus Toledo, Ohio—HL-071556
  2. University of Minnesota, Twin Cities
    Minneapolis, Minnesota—HL-072734
  3. University of Virginia
    Charlottesville, Virginia—HL-072735
  4. Mid-America Heart Institute of
    St. Luke Hospital Kansas City, Missouri—HL-072736
  5. Beth Israel Deaconess Medical Center
    Boston, Massachusetts—HL-072737

Claudication Exercise vs. Edoluminal Revascularization, Initiated in Fiscal Year 2005

The purpose of this study is to test the hypothesis that a strategy of aortoiliac stenting and pharmacotherapy improves maximum walking duration better than a strategy of supervised rehabilitation, exercise, and pharmacotherapy for those with aortoiliac artery obstruction at 6 months. Other objectives are to compare the two treatment groups with a third group, usual care and pharmacotherapy, at 6 months, and to compare maximum walking duration change scores at 18 months, changes in free living daily activity levels, and patient-perceived quality of life among all three groups.

Obligations

Funding History:
Fiscal Year 2007—$1,898,415
Fiscal Years 2005–2006—$2,846,994
Total Funding to Date—$4,745,409

Current Active Organizations and Grant Numbers

  1. Rhode Island Hospital
    Providence, Rhode Island —HL-077221
  2. Beth Israel Deaconess Medical Center
    Boston, Massachusetts—HL-081656

Clinical Research Consortium To Improve Resuscitation Outcomes, Initiated in Fiscal Year 2004

See Chapter 11. Clinical Trials.

Community-Responsive Intervention To Reduce Cardiovascular Risk in American Indians and Alaska Natives, Initiated in Fiscal Year 2006

See Chapter 11. Clinical Trials.

Design and Analysis of Genome-Wide Association Studies, Initiated in Fiscal Year 2006

The purpose of this program is to develop and test innovative, informative, and cost-effective study designs and analytical strategies to perform genome-wide association studies on complex diseases. Strategies and tools developed through the program will be made available to the scientific community.

Obligations

Funding History:
Fiscal Year 2007—$1,758,776
Fiscal Year 2006—$1,780,137
Total Funding to Date—$3,538,913

Current Active Organizations and Grant Numbers

  1. University of Chicago
    Chicago, Illinois —HL-084689
  2. Cornell University Ithaca
    Ithaca, New York —HL-084706
  3. University of Chicago
    Chicago, Illinois —HL-084715
  4. University of Michigan at Ann Arbor
    Ann Arbor, Michigan—HL-084729
  5. University of Maryland, Baltimore
    Baltimore, Maryland—HL-084756
  6. Translational Genomics Research Institute
    Phoenix, Arizona—HL-086528

Dynamic Evaluation of Percutaneous Coronary Intervention, Initiated in Fiscal Year 1997

This program, which complements prior NHLBI percutaneous transluminal coronary angioplasty (PTCA) registries and the New Approaches to Coronary Intervention Registry, is evaluating patterns of device usage, as well as immediate and follow-up outcomes in patients undergoing percutaneous transluminal coronary revascularization. Results will provide guidance to the cardiology community in selecting appropriate therapies and in designing clinical trials to evaluate competing devices.

Obligations

Funding History:
Fiscal Year 2007—$0
Fiscal Years 1997–2006—$6,180,419
Total Funding to Date—$6,180,419

Current Active Organization and Grant Number

  1. University of Pittsburgh
    Pittsburgh, Pennsylvania—HL-033292

Family Blood Pressure Program, Initiated in Fiscal Year 1995

The objectives of this program are to identify major genes associated with high blood pressure and to investigate the interactions between genetic and environmental determinants of hypertension in defined populations, many of which consist of specific minority groups. The study consists of collaborative networks that share technology, data, skills, biological materials, and population resources.

Obligations

Funding History:
Fiscal Year 2007—$3,716,949
Fiscal Years 1995–2006—$93,226,792
Total Funding to Date—$96,943,741

Current Active Organizations and Grant Numbers

  1. University of Utah
    Salt Lake City, Utah —HL-054471
  2. Washington University
    St. Louis, Missouri —HL-054473
  3. University of Texas
    Health Science Center
    Houston, Texas—HL-054481
  4. Pacific Health Research Institute
    Honolulu, Hawaii—HL-054498
  5. University of Michigan at Ann Arbor
    Ann Arbor, Michigan—HL-054512

Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN), Initiated in Fiscal Year 2000

The purpose of this study is to document CVD and CVD risk factors in approximately 40 extended families (1,214 members from villages in Northern Alaska). Scientists seek to identify and characterize genes that contribute to CVD in this unique and understudied population.

Obligations

Funding History:
Fiscal Year 2007—$2,029,384
Fiscal Years 2000–2006—$11,838,340
Total Funding to Date—$13,867,724

Current Active Organizations and Grant Numbers

  1. MedStar Research Institute
    Hyattsville, Maryland—HL-064244
  2. Norton Sound Health Corporation
    Nome, Alaska —HL-082458
  3. Southwest Foundation for Biomedical Research
    San Antonio, Texas—HL-082490

Girls Health Enrichment Multisite Studies (GEMS), Initiated in Fiscal Year 1999

The objective of this project is to develop and test interventions to prevent obesity by decreasing weight gain during the high-risk transitional period from pre-puberty to puberty in black girls who are at risk for developing obesity. Phase I (developmental and pilot studies) was completed in FY 2002. Two sites began Phase II trials in FY 2003.

Obligations

Funding History:
Fiscal Year 2007—$0
Fiscal Years 1999–2006—$19,418,195
Total Funding to Date—$19,418,195

Current Active Organizations and Grant Numbers

  1. St. Jude Children's Research Hospital
    Memphis, Tennessee—HL-062662
  2. Stanford University
    Stanford, California —HL-062663

Heart Failure: A Controlled Trial Investigating Outcomes of Exercise (HF-ACTION), Initiated in Fiscal Year 2002

The purpose of this trial is to determine the long-term safety and effectiveness of exercise training for patients with heart failure. Patients receiving the exercise regimen also will receive standard care and will be compared with patients receiving standard care alone. Thirty-eight percent of the participants are from minority populations.

Obligations

Funding History:
Fiscal Year 2007—$2,846,477
Fiscal Years 2002–2006—$34,118,122
Total Funding to Date—$36,964,599

Current Active Organizations and Grant Numbers

  1. Duke University
    Durham, North Carolina —HL-063747
  2. Case Western Reserve University
    Henry Ford Health System
    Detroit, Michigan—HL-064250
  3. Oregon Health & Science University
    Portland, Oregon—HL-064257
  4. Washington University
    St. Louis, Missouri —HL-064264
  5. University of Colorado
    Health Sciences Center
    Denver, Colorado—HL-064265
  6. Duke University
    Durham, North Carolina —HL-066461
  7. Emory University
    Atlanta, Georgia —HL-066482
  8. Wake Forest University
    Winston-Salem, North Carolina—HL-066491
  9. Ohio State University
    Columbus, Ohio —HL-066494
  10. University of Alabama at Birmingham
    Birmingham, Alabama—HL-066497
  11. Case Western Reserve University
    Philadelphia, Pennsylvania—HL-066501
  12. Boston Medical Center
    Boston, Massachusetts —HL-068973
  13. University of California, Los Angeles
    Los Angeles, California—HL-068980

Heart Failure Clinical Research Network, Initiated in Fiscal Year 2006

See Chapter 11. Clinical Trials.

Home Automatic External Defibrillator Trial (HAT), Initiated in Fiscal Year 2002

The purpose of this trial is to compare standard response (call 9–1–1 and give cardiopulmonary resuscitation) to sudden cardiac arrest to standard response augmented with automatic external defibrillator use provided by a spouse or other family member in 7,000 survivors of an anterior wall MI. The primary end point is mortality.

Obligations

Funding History:
Fiscal Year 2007—$0
Fiscal Years 2002–2006—$17,178,972
Total Funding to Date—$17,178,972

Current Active Organization and Grant Number

  1. Seattle Institute for Cardiac Research
    Seattle, Washington—HL-067972

IMMEDIATE Trial: Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care, Initiated in Fiscal Year 2004

The purpose of this program is to study the effects of early administration of glucose, insulin, and potassium (GIK) in reducing mortality in patients from acute coronary syndrome (ACS). Patients experiencing an ACS (including AMI and unstable angina pectoris) will be treated with GIK as soon as possible in prehospital emergency medical service settings or immediately upon arrival for those presenting to emergency departments.

Obligations

Funding History:
Fiscal Year 2007—$0
Fiscal Years 2004–2006—$25,650,639
Total Funding to Date—$25,650,639

Current Active Organizations and Grant Numbers

  1. New England Medical Center Hospitals
    Boston, Massachusetts—HL-077821
  2. State University of New York
    Stony Brook, New York—HL-077822
  3. New England Medical Center Hospitals
    Boston, Massachusetts—HL-077823
  4. New England Medical Center Hospitals
    Boston, Massachusetts—HL-077826

Improved Measures of Diet and Physical Activity for the Genes and Environment, Initiated in Fiscal Year 2007

The purpose of this program is to support the development of technology to make precise, quantitative measurements of personal exposure to environmental chemical or biological agents, diet, physical activity, and psychosocial stress.

Obligations

Funding History:
Fiscal Year 2007—$2,632,681
Total Funding to Date—$2,632,681

Current Active Organizations and Grant Numbers

  1. University of Pittsburgh
    Pittsburgh, Pennsylvania—HL-091736
  2. Massachusetts Institute of Technology
    Cambridge, Massachusetts—HL-091737
  3. Princeton Multimedia Technologies Corporation
    Princeton, New Jersey—HL-091738

Network for Cardiothoracic Surgical Investigation in Cardiovascular Medicine, Initiated in Fiscal Year 2007

See Chapter 11. Clinical Trials.

NHLBI Clinical Proteomics Program, Initiated in Fiscal Year 2005

The purpose of this program is to promote systematic, comprehensive, large-scale validation of existing and new candidate protein markers that are appropriate for routine use in the diagnosis and management of heart, lung, and blood diseases and sleep disorders. The Program will facilitate validation of protein panels that may be used to predict disease susceptibility or to assist in differential diagnosis, disease staging, selection of individualized therapies, or monitoring of treatment responses. It will also establish a high-quality education and skills development program to ensure that scientists develop the expertise needed to address the complex, multifaceted challenges in clinical proteomics.

Obligations

Funding History:
Fiscal Year 2007—$4,920,952
Fiscal Years 2005–2006—$10,024,329
Total Funding to Date—$14,945,281

Current Active Organizations and Grant Numbers

  1. Mayo Clinic College of Medicine
    Rochester, Minnesota—HL-081331
  2. Vanderbilt University
    Nashville, Tennessee —HL-081332
  3. University of Colorado
    Denver, Colorado —HL-081335
  4. Massachusetts General Hospital
    Boston, Massachusetts—HL-081341

Occluded Artery Trial (OAT), Initiated in Fiscal Year 1999

The purpose of this study is to determine whether percutaneous revascularization to open an occluded artery within a few days or as long as a month following an acute MI in asymptomatic patients improves their outcome. Although the benefits of early restoration of blood flow following an acute MI have been well-established, it is not known whether later intervention is also beneficial. The trial is in its follow-up phase.

Funding History:
Fiscal Year 2007—$1,452,378
Fiscal Years 1999–2006—$17,224,514
Total Funding to Date—$18,676,892

Current Active Organizations and Grant Numbers

  1. New York University
    School of Medicine
    New York, New York—HL-062509
  2. Maryland Medical Research
    Institute, Inc.
    Baltimore, Maryland—HL-062511

Partnership Programs To Reduce Cardiovascular Health Disparities, Initiated in Fiscal Year 2004

The objectives of this study are to improve the provider and patient approaches to treatment of hypertension and diabetes, modify physician-related barriers to minority enrollment in clinical trials, improve patient adherence to treatment plans, and build sustainable research programs at minority-serving institutions.

Obligations

Funding History:
Fiscal Year 2007—$7,330,477
Fiscal Years 2004–2006—$20,929,126
Total Funding to Date—$28,259,603

Current Active Organizations and Grant Numbers

  1. Bon Secours Hospital Baltimore, Inc.
    Baltimore, Maryland—HL-079150
  2. University of Maryland
    Baltimore Professional School
    Baltimore, Maryland—HL-079151
  3. Queen's Medical Center
    Honolulu, Hawaii —HL-079152
  4. Cooper Green Hospital
    Birmingham, Alabama —HL-079153
  5. Emory University
    Atlanta, Georgia —HL-079156
  6. Denver Health and Hospital Authority
    Denver, Colorado—HL-079160
  7. University of Hawaii at Manoa
    Honolulu, Hawaii —HL-079163
  8. University of Alabama at Birmingham
    Birmingham, Alabama—HL-079171
  9. University of Colorado
    Health Sciences Center
    Denver, Colorado—HL-079208
  10. Morehouse School of Medicine
    Atlanta, Georgia —HL-079214
  11. Jackson Hinds Comprehensive
    Health Center
    Jackson, Mississippi—HL-079378
  12. University of Mississippi
    Medical Center
    Jackson, Mississippi—HL-079458

Pediatric Heart Network, Initiated in Fiscal Year 2006

See Chapter 11. Clinical Trials.

Pharmacogenetics Research Network, Initiated in Fiscal Year 2001

The purpose of this study is to establish a network to systematically evaluate candidate genes that may influence pharmacologic response to drug treatments for arrhythmia, heart failure, hypertension, and lipid disorders. Investigators seek to identify gene polymorphisms capable of predicting drug toxicity and efficacy. One of the projects has 38 percent minority participation.

Obligations

Funding History:
Fiscal Year 2007—$8,770,916
Fiscal Years 2001–2006—$48,524,584
Total Funding to Date—$57,295,500

Current Active Organizations and Grant Numbers

  1. Vanderbilt University
    Nashville, Tennessee —HL-065962
  2. Children's Hospital and Research Center
    Oakland, California—HL-069757
  3. Stanford University
    Stanford, California —GM-061374

Preventing Overweight Using Novel Dietary Strategies (POUNDS LOST), Initiated in Fiscal Year 2003

The purpose of this study is to compare the effects of four diets low in saturated fat and differing in macronutrient composition on weight loss and its maintenance in 800 overweight or obese adults. The diet consists of moderate fat (40 percent energy) or low fat (20 percent energy) with two different protein levels (15 and 25 percent). Seventeen percent of the participants are from minority populations.

Obligations

Funding History:
Fiscal Year 2007—$0
Fiscal Years 2003–2006—$6,779,823
Total Funding to Date—$6,779,823

Current Active Organization and Grant Number

  1. Harvard School of Public Health
    Boston, Massachusetts—HL-073286

Programs in Gene by Environmental Interaction (PROGENI), Initiated in Fiscal Year 2002*

The purpose of this study is to identify novel genes that interact with specific environmental exposures to modify risk factors for heart, lung, and blood diseases and sleep disorders. The genetic aspects of response to environmental change and related biological mechanisms will be studied using short-term, focused interventions in black families. Subgroups will be identified based on genotypes that are most likely to benefit from targeted environmental changes designed to reduce the development or progression of heart, lung, and blood diseases or sleep disorders.

Obligations

Funding History:
Fiscal Year 2007—$1,459,246
Fiscal Years 2002–2006—$46,713,444
Total Funding to Date—$48,172,690

Current Active Organizations and Grant Numbers

  1. Tulane University
    New Orleans, Louisiana —HL-072507
  2. LSU Pennington Biomedical
    Research Center
    Baton Rouge, Louisiana—HL-072510
  3. University of Maryland
    Baltimore Professional School
    Baltimore, Maryland—HL-072515
  4. Johns Hopkins University
    Baltimore, Maryland —HL-072518
  5. University of Alabama at Birmingham
    Birmingham, Alabama—HL-072524

*Formerly known as Interaction of Gene and Environment in Shaping Risk Factors for Heart, Lung, and Blood Diseases and Sleep Disorders.

Programs of Excellence in Nanotechnology, Initiated in Fiscal Year 2005

The purpose of this program is to establish multidisciplinary teams to develop nanotechnology and biomolecular engineering tools and methodologies to detect and analyze atherosclerotic plaque formation. The program presents an unique opportunity for research collaboration and skills training by bringing bioengineering and nanotechnology solutions into medicine and vice versa.

Obligations

Funding History:
Fiscal Year 2007—$10,992,900
Fiscal Years 2005–2006—$17,553,560
Total Funding to Date—$28,546,460

Current Active Organizations and Grant Numbers

  1. Emory University
    Atlanta, Georgia —HL-080711
  2. Burnham Institute for Medical Research
    La Jolla, California—HL-080718
  3. Washington University
    St. Louis, Missouri —HL-080729
  4. Massachusetts General Hospital
    Boston, Massachusetts—HL-080731

Programs of Genomic Applications (PGAs) for Heart, Lung, and Blood Diseases, Initiated in Fiscal Year 2000

The goal of this program is to develop information, tools, and resources to link genes to biological function. Specifically, researchers seek to identify human genes relevant to heart, lung, blood, and sleep functions. In addition, the PGAs will establish training programs for NHLBI-supported investigators in the use of genomic information and technologies.

Obligations

Funding History:
Fiscal Year 2007—$14,039,424
Fiscal Years 2000–2006— $195,107,611
Total Funding to Date—$209,147,035

Current Active Organizations and Grant Numbers

  1. Medical College of Wisconsin
    Milwaukee, Wisconsin—HL-066579
  2. University of California, San Francisco
    San Francisco, California—HL-066600
  3. Jackson Laboratory
    Bar Harbor, Maine —HL-066611
  4. University of California, Los Angeles
    Los Angeles, California—HL-066621
  5. University of Washington
    Seattle, Washington —HL-066642
  6. University of California
    Lawrence Berkeley Laboratory
    Berkeley, California—HL-066681
  7. University of Washington
    Seattle, Washington —HL-066682

Stop Atherosclerosis in Native Diabetics Study (SANDS), Initiated in Fiscal Year 2002

This study will address the high incidence of CVD in American Indians who have a high prevalence of diabetes, but relatively low levels of LDL cholesterol and blood pressure. It will compare aggressive lowering of LDL cholesterol and blood pressure to the usual care standard.

Obligations

Funding History:
Fiscal Year 2007—$197,305
Fiscal Years 2002–2006— $11,079,036
Total Funding to Date—$11,276,341

Current Active Organization and Grant Number

  1. MedStar Research Institute
    Hyattsville, Maryland—HL-067031

Strong Heart Study, Initiated in Fiscal Year 1988

The objectives of this study are to survey CVD morbidity and mortality rates among three geographically diverse groups of American Indians and to estimate their levels of CVD risk factors. Phases II and III of the cohort study extended surveillance of community mortality and assessed development of CVD and changes in CVD risk factors. In Phase III, investigators added a substudy of asthma and a pilot family study. Phase IV expanded the family study to 120 families comprising 3,600 members to investigate genetic and environmental contributors of CVD. Phase V will examine the family study cohort to assess genetic relationships to risk factor change over a 5‑year period.

Obligations

Funding History:
Fiscal Year 2007—$6,182,306
Fiscal Years 1988–2006—$57,974,143
Total Funding to Date—$64,156,449

Current Active Organizations and Grant Numbers

  1. MedStar Research Institute
    Hyattsville, Maryland—HL-041642
  2. Missouri Breaks Research, Inc.
    Timberlake, South Dakota—HL-041652
  3. University of Oklahoma
    Health Sciences Center
    Oklahoma City, Oklahoma—HL-041654
  4. Southwest Foundation for
    Biomedical Research
    San Antonio, Texas—HL-065520
  5. Weill Medical College of
    Cornell University
    New York, New York—HL-065521

Surgical Treatment for Ischemic Heart Failure (STICH), Initiated in Fiscal Year 2002

The purpose of this clinical trial is to determine whether CABG plus intensive medical therapy improves long-term survival of patients with heart failure and left ventricular (LV) dysfunction who have coronary artery disease amenable to surgical revascularization, compared to medical therapy alone; and to determine whether CABG plus surgical ventricular restoration to a more normal LV size improves survival free of subsequent hospitalizations of patients with anterior LV dysfunction, compared to CABG alone.

Obligations:

Funding History:
Fiscal Year 2007—$8,912,357
Fiscal Years 2002–2006—$25,529,882
Total Funding to Date—$34,442,239

Current Active Organizations and Grant Numbers

  1. Thomas Jefferson University
    Philadelphia, Pennsylvania—HL-069009
  2. Mayo Clinic College of Medicine
    Rochester, Minnesota—HL-069010
  3. Duke University
    Durham, North Carolina —HL-069011
  4. Northwestern University
    Chicago, Illinois —HL-069012
  5. Duke University
    Durham, North Carolina —HL-069013
  6. Duke University
    Durham, North Carolina —HL-069015
  7. University of Southern California
    Los Angeles, California—HL-072683

Trial of Activity for Adolescent Girls (TAAG), Initiated in Fiscal Year 2000

See Chapter 11. Clinical Trials.

Weight Loss in Obese Adults With Cardiovascular Risk Factors: Clinical Interventions, Initiated in Fiscal Year 2006

See Chapter 11. Clinical Trials.

Weight Loss Maintenance (WLM), Initiated in Fiscal Year 2003

The purpose of this multicenter trial is to evaluate the effectiveness of two strategies to maintain weight loss for 2½ years in approximately 800 overweight or obese adults. Individuals who are taking medication for hypertension of dyslipidemia or who are diabetic enter a 6-month weight program. Those who lose at least 9 pounds are randomized into one of three groups: one that provides monthly personal contacts with a trained interventionist, primarily by telephone; one that provides frequent contacts through an interactive Web-based program; or usual care. Forty percent of the participants will be black.

Obligations

Funding History:
Fiscal Year 2007—$2,150,858
Fiscal Years 2003–2006—$15,168,042
Total Funding to Date—$17,318,900

Current Active Organizations and Grant Numbers

  1. Kaiser Foundation Research Institute
    Oakland, California—HL-068676
  2. Duke University
    Durham, North Carolina —HL-068734
  3. Kaiser Foundation Research Institute
    Oakland, California—HL-068790
  4. Johns Hopkins University
    Baltimore, Maryland —HL-068920
  5. LSU Pennington Biomedical
    Research Center
    Baton Rouge, Louisiana—HL-068955

Lung Diseases Program

Apnea Positive Pressure Long-Term Efficacy Study (APPLES), Initiated in Fiscal Year 2002

The purpose of this study is to evaluate the effectiveness of continuous positive airway pressure (CPAP) therapy to provide significant, stable, and long-term neurocognitive or other benefits to patients with obstructive sleep apnea (OSA). Investigators will identify specific neurocognitive deficits associated with OSA and determine which ones are reversible and most sensitive to the effects of CPAP therapy.

Obligations

Funding History:
Fiscal Year 2007—$1,532,037
Fiscal Years 2002–2006—$12,542,181
Total Funding to Date—$14,074,218

Current Active Organization and Grant Number

  1. Stanford University
    Stanford, California —HL-068060

Asthma Clinical Research Network (ACRN) Phase II, Initiated in Fiscal Year 2003

See Chapter 11. Clinical Trials.

Centers for Reducing Asthma Disparities, Initiated in Fiscal Year 2002

The purpose of this study is to establish cooperative centers of research to reduce asthma disparities between whites and minorities and economically disadvantaged populations. The mission of the centers, comprising partnerships between minority-servicing medical institutions and research-intensive institutions, is to promote interdisciplinary investigation of factors that contribute to disparities in asthma, accelerate development and evaluation of strategies to promote effective asthma management among minority and economically disadvantaged populations, encourage training and career development for minority clinical research investigators, and improve the effectiveness of NHLBI-supported research-intensive institutions in developing and sustaining culturally appropriate research and demonstration activities on reducing disparities.

Obligations

Funding History:
Fiscal Year 2007—$0
Fiscal Years 2002–2006—$27,350,819
Total Funding to Date—$27,350,819

Current Active Organizations and Grant Numbers

  1. Meharry Medical College
    Nashville, Tennessee —HL-072431
  2. Howard University
    Washington, DC —HL-072433
  3. Rhode Island Hospital
    Providence, Rhode Island —HL-072438
  4. Johns Hopkins University
    Baltimore, Maryland —HL-072455
  5. Vanderbilt University
    Nashville, Tennessee —HL-072471
  6. Northwestern University
    Chicago, Illinois —HL-072478
  7. Hektoen Institute for Medical Research
    Chicago, Illinois—HL-072496
  8. University of Puerto Rico
    Medical Sciences
    San Juan, Puerto Rico—HL-072519

Childhood Asthma Management Program–Continuation Study (CAMP–CS)/Phase III, Initiated in Fiscal Year 2007

The objective of this observational study is to follow the original CAMP cohort for 4 more years (through ages 21–29) to determine clinical and genetic risk factors for patterns of lung function decline indicative of chronic air flow obstruction in later adulthood; 31 percent of the participants are from minority groups.

Obligations

Funding History:
Fiscal Year 2007—$2,077,278
Total Funding to Date—$2,077,278

Current Active Organizations and Grant Numbers

  1. Washington University
    St. Louis, Missouri —HL-075232
  2. Hospital for Sick Children
    Toronto, Ontario —HL-075407
  3. Johns Hopkins University
    Baltimore, Maryland —HL-075408
  4. Asthma, Inc.
    Seattle, Washington —HL-075409
  5. University of California, San Diego
    La Jolla, California—HL-075415
  6. National Jewish Medical
    and Research Center
    Denver, Colorado—HL-075416
  7. Johns Hopkins University
    Baltimore, Maryland —HL-075417
  8. Brigham and Women's Hospital
    Boston, Massachusetts—HL-075419
  9. University of New Mexico
    Albuquerque, New Mexico—HL-075420

Childhood Asthma Research and Education (CARE) Network, Initiated in Fiscal Year 1999

See Chapter 11. Clinical Trials.

Clinical Trial of Acid Reflux Therapy in Asthma, Initiated in Fiscal Year 2003

The purpose of this clinical trial is to test the hypothesis that treatment of gastroesophageal reflux with proton-pump inhibitors will reduce the frequency of exacerbations in patients with inadequately controlled asthma. Thirty-four percent of the participants are black.

Obligations

Funding History:
Fiscal Year 2007—$662,283
Fiscal Years 2003–2006—$3,083,552
Total Funding to Date—$3,745,835

Current Active Organization and Grant Number

  1. Johns Hopkins University
    Baltimore, Maryland —HL-072968

Collaborative Program in Bronchopulmonary Dysplasia, Initiated in Fiscal Year 1999

The objectives of this program are to support a multi-institutional collaborative research effort by providing a well-defined model of prematurity and bronchopulmonary dysplasia to investigators, and to study mechanisms of lung pathobiology that underlie development of chronic lung disease of prematurity.

Obligations

Funding History:
Fiscal Year 2007—$2,526,747
Fiscal Years 1999–2006—$36,731,072
Total Funding to Date—$39,257,819

Current Active Organizations and Grant Numbers

  1. Southwest Foundation
    for Biomedical Research
    San Antonio, Texas—HL-052636
  2. Duke University
    Durham, North Carolina —HL-052638
  3. University of California, San Francisco
    San Francisco, California—HL-056061
  4. National Jewish Medical
    and Research Center
    Denver, Colorado—HL-056263
  5. Barnes Jewish Hospital
    St. Louis, Missouri —HL-063387
  6. National Jewish Medical
    and Research Center
    Denver, Colorado—HL-063397
  7. University of Texas
    Southwestern Medical Center
    Dallas, Texas—HL-063399
  8. University of Rochester
    Rochester, New York —HL-063400
  9. University of Texas
    Southwestern Medical Center
    Dallas, Texas—HL-075900

COPD Clinical Research Network, Initiated in Fiscal Year 2003

See Chapter 11. Clinical Trials.

Early Antipseudomonal Therapy in Cystic Fibrosis, Initiated in Fiscal Year 2004

The purpose of this study is to determine a safe, effective, and systematic approach for treating young children (ages 1 to 12 years) with cystic fibrosis who are found to be infected with Pseudomonas aemginosa (Pa). The goal is to intervene with antipseudomonal therapy at the first isolation of Pa to delay or prevent chronic infections that lead to irreversible lung destruction.

Obligations

Funding History:
Fiscal Year 2007—$923,625
Fiscal Years 2004–2006—$3,145,273
Total Funding to Date—$4,068,898

Current Active Organization and Grant Number

  1. Children's Hospital
    and Regional Medical Center
    Seattle, Washington—HL-080310

Genetic Epidemiology of COPD

The purpose of this study is to perform a genome-wide association analysis to identify the genetic risk factors that determine susceptibility for COPD and COPD-related phenotypes in a large biracial population.

Obligations

Funding History:
Fiscal Year 2007—$6,113,536
Total Funding to Date—$6,113,536

Current Active Organizations and Grant Numbers

  1. Brigham and Women's Hospital
    Boston, Massachusetts—HL-089856
  2. National Jewish Medical and
    Research Center
    Denver, Colorado—HL-089897

Idiopathic Pulmonary Fibrosis Clinical Research Network, Initiated in Fiscal Year 2005

See Chapter 11. Clinical Trials.

Pharmacogenetics of Asthma Treatment, Initiated in Fiscal Year 2000

The objective of this project is to bring together research experts in asthma, epidemiology, statistics, bioinformatics, physiology, clinical trials, genetics, and genomics to focus on the pharmacogenetics of asthma treatment.

Obligations

Funding History:
Fiscal Year 2007—$3,190,981
Fiscal Years 2000–2006—$17,494,738
Total Funding to Date—$20,685,719

Current Active Organization and Grant Number

  1. Brigham and Women's Hospital
    Boston, Massachusetts—HL-065899

Prospective Investigation of Pulmonary Embolism Diagnosis III (PIOPED III), Initiated in Fiscal Year 2005

The purpose of this study is to determine the diagnostic accuracy of gadolinium-enhanced magnetic resonance angiography of the pulmonary arteries in combination with magnetic resonance venography of the lower extremities for the detection of acute venous thromboembolic disease.

Obligations

Funding History:
Fiscal Year 2007—$1,518,303
Fiscal Years 2005–2006—$6,643,681
Total Funding to Date—$8,161,984

Current Active Organizations and Grant Numbers

  1. Massachusetts General Hospital
    Boston, Massachusetts—HL-077149
  2. University of Michigan
    Ann Arbor, Michigan —HL-077150
  3. University of Calgary
    Calgary, Alberta —HL-077151
  4. Emory University
    Atlanta, Georgia —HL-077153
  5. Washington University
    St. Louis, Missouri —HL-077154
  6. George Washington University
    Washington, DC —HL-077155
  7. St. Joseph Mercy-Oakland
    Pontiac, Michigan —HL-077358
  8. New York University
    New York, New York —HL-081593
  9. St. Joseph Mercy-Oakland
    Pontiac, Michigan —HL-081594

Randomized Controlled Study of Adenotonsillectomy for Childhood Sleep Apnea, Initiated in Fiscal Year 2006

The purpose of this randomized controlled study is to compare adenotonsillectomy versus no surgery for OSA in children.

Obligations

Funding History:
Fiscal Year 2007—$2,387,691
Fiscal Year 2006—$2,267,140
Total Funding to Date—$4,654,831

Current Active Organizations and Grant Numbers

  1. Case Western Reserve University
    Cleveland, Ohio—HL-083075
  2. University of Pennsylvania
    Philadelphia, Pennsylvania—HL-083129

Sleep Heart Health Study, Initiated in Fiscal Year 1999

The purpose of this multicenter observational study is to determine the degree to which sleep apnea is an independent or contributing risk factor for the development of cardiovascular or cerebrovascular disease.

Obligations

Funding History:
Fiscal Year 2007—$625,846
Fiscal Years 1999–2006—$20,511,241
Total Funding to Date—$21,137,087

Current Active Organizations and Grant Numbers

  1. University of California, Davis
    Davis, California—HL-053916
  2. University of Arizona
    Tucson, Arizona —HL-053934
  3. Johns Hopkins University
    Baltimore, Maryland —HL-053937
  4. University of Arizona
    Tucson, Arizona —HL-053938
  5. Boston University
    Boston, Massachusetts —HL-053941
  6. Missouri Breaks Research, Inc.
    Timberlake, South Dakota—HL-063429
  7. Case Western Reserve University
    Cleveland, Ohio —HL-063463
  8. Johns Hopkins University
    Baltimore, Maryland —HL-064360
  9. University of Pittsburgh
    Pittsburgh, Pennsylvania—HL-077813

Study of Acid Reflux Therapy for Children With Asthma, Initiated in Fiscal Year 2006

The purpose of this randomized controlled clinical trial is to investigate whether an approved proton-pump inhibitor lansoprazole will reduce asthma exacerbations in children with poorly controlled asthma, ages 6–16 years. Thirty percent of the participants will be from minority populations.

Obligations

Funding History:
Fiscal Year 2007—$846,333
Fiscal Year 2006—$774,454
Total Funding to Date—$1,620,787

Current Active Organizations and Grant Numbers

  1. Emory University
    Atlanta, Georgia —HL-080433
  2. Johns Hopkins University
    Baltimore, Maryland —HL-080450

Blood Diseases and Resources

Blood and Marrow Transplant Clinical Research Network, Initiated in Fiscal Year 2001

See Chapter 11. Clinical Trials.

Center for Human Cell Therapy, Initiated in Fiscal Year 2004

The purpose of this Center is to serve as a unique resource to facilitate the development of new cellular therapies for a wide range of human diseases, especially heart, lung, and blood diseases and sleep disorders.

Obligations

Funding History:
Fiscal Year 2007—$2,096,324
Fiscal Years 2004–2006—$7,281,374
Total Funding to Date—$9,377,698

Current Active Organization and Grant Number

  1. CBR Institute for Biomedical Research
    Boston, Massachusetts—HL-074355

Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair (FOCUS), Initiated in Fiscal Year 2003

The purpose of this trial is to test whether a more aggressive transfusion strategy that maintains postoperative Hgb levels above 10 g/dl improves functional outcome in cardiovascular patients who are over age 50 and undergoing surgical hip fracture surgery compared to a more conservative strategy that withholds blood transfusion until the patient develops symptoms of anemia.

Obligations

Funding History:
Fiscal Year 2007—$1,974,477
Fiscal Years 2003–2006—$8,804,219
Total Funding to Date—$10,778,696

Current Active Organizations and Grant Numbers

  1. Robert Wood Johnson Medical School
    University of Medicine and Dentistry
    of New Jersey
    Piscataway, New Jersey —HL-073958
  2. Maryland Medical Research Institute, Inc.
    Baltimore, Maryland—HL-074815

Sickle Cell Disease Clinical Research Network, Initiated in Fiscal Year 2006

See Chapter 11. Clinical Trials.

Stroke With Transfusions Changing to Hydroxyurea (SWITCH), Initiated in Fiscal Year 2005

The purpose of this Phase III clinical trial is to compare standard therapy (transfusions and chelation) with alternative therapy (hydroxyurea and phlebotomy) for the prevention of secondary stroke and management of iron overload in children with sickle cell anemia. Additional objectives include comparisons of growth and development, frequency of nonstroke neurological and other sickle-related events, and quality of life. The patient population will be black.

Obligations

Funding History:
Fiscal Year 2007—$3,531,426
Fiscal Years 2005–2006—$7,277,340
Total Funding to Date—$10,808,766

Current Active Organizations and Grant Numbers

  1. St. Jude Children's Research Hospital
    Memphis, Tennessee—HL-078787
  2. Rho Federal Systems Division, Inc.
    Chapel Hill, North Carolina—HL-078987

Thalassemia (Cooley's Anemia) Clinical Research Network

See Chapter 11. Clinical Trials.

Transfusion Medicine/Hemostasis Clinical Research Network, Initiated in Fiscal Year 2002

See Chapter 11. Clinical Trials.

NHLBI Research Centers (P50) Programs

Specialized Centers of Research (P50), Specialized Centers of Clinically Oriented Research (P50), and Centers of Excellence in Translational Human Stem Cell Research (P50) Programs

The NHLBI initiated the SCOR program in 1971 to encourage translational research—converting basic science findings to the clinic—in high priority areas. The SCOR concept emphasizes multidisciplinary research (i.e., basic science and clinical investigations) on diseases relevant to the Institute's mission. In 2002, the NHLBI revised the SCOR program—primarily on recommendation from the NHLBAC—to place more emphasis on clinical research projects. The newly developed SCCOR program still requires clinical and basic scientists to work together on a unified theme, but now requires at least 50 percent of the projects to be clinical. The Centers of Excellence in Translational Human Stem Cell Research was initiated in 2005 to accelerate the translation of basic scientific discoveries in human stem cell biology to new treatments for patients. Listed below is the funding history for the individual SCORs/SCCORs and Centers of Excellence supported by the Institute.

Obligations (Dollars in Thousands)

Area of Concentration Period of Operation Prior to
FY 2007
FY 2007 Total to Date
Heart and Vascular Diseases Program        
Cardiac Dysfunction and Disease (SCCOR)
2005– $ 33,420 $ 16,677 $ 50,097
Pediatric Heart Developmnt and Disease (SCCOR)
2004– 39,419 12,411 51,830
Vascular Injury, Repair, and Remodeling (SCCOR)
2006– 15,324 14,924 30,248
Subtotal, Heart and Vascular Diseases Program   88,163 44,012 132,175
Lung Diseases Program        
Airway Biology and Pathogenesis of Cystic Fibrosis
1988– 66,004 3,622 69,626
Cellular and Molecular Mechanisms of Asthma
2007– 11,276 11,276
Host Factors in Chronic Lung Diseases (SCCOR)
2006– 7,939 7,868 15,807
Pathobiology of Fibrotic Lung Disease
1998– 47,525 5,767 53,292
Pathobiology of Lung Development
2007– 6,379 6,379
Translational Research in Acute Lung Injury (SCCOR)
2003– 47,961 12,199 60,160
Subtotal, Lung Diseases Program   169,429 47,111 216,540
Blood Diseases and Resources Program        
Hemostatic and Thrombotic Diseases (SCCOR)
2006– 8,063 8,002 16,065
Transfusion Biology and Medicine (SCCOR)
2005– 8,859 4,425 13,284
Subtotal, Blood Diseases and Resources Program   16,922 12,427 29,349
Total, Specialized Centers of Research (P50)   274,514 103,550 378,064
Centers of Excellence in Translational Human Stem Cell Research 2005– 2,962 1,411 4,373
Subtotal, Centers of Excellence in Translational Human Stem Cell Research   2,962 1,411 4,373
Total (P50)   $277,476 $104,961 $382,437

Heart and Vascular Diseases Program

Cardiac Dysfunction and Disease

The purpose of this SCCOR is to foster multidisciplinary research on clinically relevant questions related to dysfunction and disease of the myocardium. The program will enable rapid application of basic science findings to the prevention, diagnosis, and treatment of cardiac disorders, including ischemic and other cardiomyopathies, left ventricular dysfunction, metabolic abnormalities, heart failure, and rhythm disturbances. Because some segments of the population disproportionately suffer from heart disease, research that addresses issues of health disparity will be emphasized.

Obligations

Fiscal Year 2007—$16,677,106

Current Active Organizations and Grant Numbers

  1. Columbia University
    Health Science Center
    New York, New York—HL-077096
  2. University of Alabama at Birmingham
    Birmingham, Alabama—HL-077100
  3. University of Cincinnati
    Cincinnati, Ohio —HL-077101
  4. Cleveland Clinical Lerner College
    Cleveland, Ohio—HL-077107
  5. Washington University
    St. Louis, Missouri —HL-077113

Pediatric Heart Development and Disease

The purpose of this SCCOR is to foster multidisciplinary collaborations so that basic research advances can be translated rapidly to clinical care for children with heart disease. Research focus ranges from the genetic basis of heart valve disease to clinical trials of novel surgical strategies for congenital heart disease repair and immune modulation in pediatric heart transplantation. Two of the centers will have Clinical Research Skills Development Cores to train fellows and junior faculty in clinical research methods.

Obligations

Fiscal Year 2007—$12,410,785

Current Active Organizations and Grant Numbers

  1. Children's Hospital Medical Center
    Cincinnati, Ohio—HL-074728
  2. Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania—HL-074731
  3. University of Pittsburgh
    Pittsburgh, Pennsylvania—HL-074732
  4. Children's Hospital
    Boston, Massachusetts —HL-074734

Vascular Injury, Repair, and Remodeling

The purpose of this SCCOR is to foster multidisciplinary, clinically relevant research on vascular injury, repair, and remodeling. The program emphasizes development and translation of basic discoveries to understand the mechanisms of vascular disease; improved detection, characterization, staging, and management of vascular disease through use of cutting-edge methodologies, such as nanotechnology, molecular imaging, genomics, proteomics, and quantitative systems analysis; and development of new methods to treat vascular diseases such as cell- and gene-based therapies for regenerative medicine.

Obligations

Fiscal Year 2007—$14,923,676

Current Active Organizations and Grant Numbers

  1. Washington University
    St. Louis, Missouri —HL-083762
  2. University of Texas Health
    Science Center
    Houston, Texas—HL-083794
  3. University of Pennsylvania
    Philadelphia, Pennsylvania—HL-083799
  4. Stanford University
    Stanford, California —HL-083800
  5. Boston University Medical Campus
    Boston, Massachusetts—HL-083801
  6. Beth Israel Deaconess Medical Center
    Boston, Massachusetts—HL-083813

Lung Diseases Program

Airway Biology and Pathogenesis of Cystic Fibrosis

The goals of this SCOR are to investigate the basic mechanisms underlying cystic fibrosis, develop new hypotheses, and apply innovative strategies for approaching clinical and fundamental issues.

Obligations

Fiscal Year 2007—$3,622,413

Current Active Organizations and Grant Numbers

  1. University of North Carolina
    at Chapel Hill
    Chapel Hill, North Carolina—HL-060280
  2. University of Iowa
    Iowa City, Iowa —HL-061234

Chronic Obstructive Pulmonary Disease

The purpose of this SCCOR is to foster multidisciplinary research to accelerate progress in the diagnosis, prevention, and treatment of COPD. The program will include a broad spectrum of basic and clinical research that will encompass animal models of COPD pathogenesis, human proteomic, genetic and genomic investigations, technologically refined disease phenotypes classification, and the development of new experimental therapeutic interventions.

Obligations

Fiscal Year 2007—$11,275,633

Current Active Organizations and Grant Numbers

  1. Washington University
    St. Louis, Missouri —HL-084922
  2. Weill Medical College
    of Cornell University
    New York, New York—HL-084936
  3. Johns Hopkins University
    Baltimore, Maryland —HL-084945
  4. University of Pittsburgh
    Pittsburgh, Pennsylvania—HL-084948

Host Factors in Chronic Lung Diseases

The purpose of this SCCOR is to identify alterations in host responses and lung homeostasis and to determine how the dysregulation contributes to development or progression of chronic lung diseases. Enhanced understanding of these processes should facilitate identification of new targets for intervention, providing the basis for development of new therapeutic options for prevention and treatment of chronic lung diseases.

Obligations

Fiscal Year 2007—$7,867,941

Current Active Organizations and Grant Numbers

  1. Duke University
    Durham, North Carolina —HL-084917
  2. Children's Hospital
    Pittsburgh, Pennsylvania —HL-084932
  3. University of North Carolina
    Chapel Hill, North Carolina—HL-084934

Neurobiology of Sleep and Sleep Apnea

The objective of this SCOR is to integrate molecular, cellular, and genetic approaches to sleep control with clinical investigations on the etiology and pathogenesis of sleep disorders, particularly sleep apnea.

Obligations

Fiscal Year 2007—$5,767,416

Current Active Organizations and Grant Numbers

  1. University of Pennsylvania
    Philadelphia, Pennsylvania—HL-060287
  2. Beth Israel Deaconess Medical Center
    Boston, Massachusetts—HL-060292
  3. University of California, Los Angeles
    Los Angeles, California—HL-060296

Pulmonary Vascular Disease

The objective of this SCCOR is to facilitate multidisciplinary research that proposes original hypotheses and applies cutting-edge approaches, including genomics and proteomics, to clinical issues in pulmonary vascular disease.

Obligations

Fiscal Year 2007—$6,379,355

Current Active Organizations and Grant Numbers

  1. University of Colorado at Denver
    Denver, Colorado—HL-084923
  2. Johns Hopkins University
    Baltimore, Maryland —HL-084946

Translational Research in Acute Lung Injury

The purpose of this SCCOR is to foster multidisciplinary research to improve the prevention, diagnosis, and treatment of acute lung injury and its more severe form—adult respiratory distress syndrome. This program includes Phase II clinical trials and studies of molecular mechanisms of inflammation and coagulation, gene and protein expression, and cell and animal models of lung injury.

Obligations

Fiscal Year 2007—$12,199,089

Current Active Organizations and Grant Numbers

  1. Johns Hopkins University
    Baltimore, Maryland —HL-073994
  2. University of Washington
    Seattle, Washington —HL-073996
  3. University of California, San Francisco
    San Francisco, California—HL-074005
  4. University of Michigan at Ann Arbor
    Ann Arbor, Michigan—HL-074024

Blood Diseases and Resources Program

Hemostatic and Thrombotic Disorders

The purpose of this SCCOR is to conduct multidisciplinary research to improve the prevention, diagnosis, and treatment of thrombotic and bleeding disorders. The program will support rapid translation of basic science findings into clinical application.

Obligations

Fiscal Year 2007—$8,001,975

Current Active Organizations and Grant Numbers

  1. Vanderbilt University
    Nashville, Tennessee —HL-081009
  2. Cleveland Clinic Lerner College
    Cleveland, Ohio —HL-081011
  3. University of Pennsylvania
    Philadelphia, Pennsylvania—HL-081012

Transfusion Biology and Medicine

The purpose of this SCCOR is to foster new approaches for improving the availability, efficacy, safety, and quality of blood and blood products for therapeutic uses. One of the centers has a large minority population.

Obligations

Fiscal Year 2007—$4,424,761

Current Active Organizations and Grant Numbers

  1. Puget Sound Blood Center
    Seattle, Washington —HL-081015
  2. University of California, San Francisco
    San Francisco, California—HL-081027

Centers of Excellence in Translational Human Stem Cell Research (P50) Program

The purpose of this program is to stimulate multidisciplinary collaboration among basic stem cell biologists, researchers, and clinicians with disease-specific expertise; physicians and surgeons skilled in innovative modes of cell delivery; and investigators experienced in developing and assessing animal models of human diseases to conduct projects such as preclinical studies for cell-based therapy employing human stem cells in animal models. Research findings will ultimately lead to innovative approaches for the prevention, treatment, and cure of disease, and will accelerate the translation of basic scientific discoveries into new therapies.

Obligations

Fiscal Year 2007—$1,410,801

Current Active Organization and Grant Number

  1. University of California, Davis
    Davis, California—HL-085036

Comprehensive Sickle Cell Centers (U54) Program

The Comprehensive Sickle Cell Centers (CSCC) were instituted in FY 1972 to bridge the gap between research and service by combining basic and clinical research, clinical trials and applications training, and community service projects into one program. The patients recruited for the clinical studies are primarily from minority populations.

Obligations

Fiscal Year 2007—$23,559,624

Current Active Organizations and Grant Numbers

  1. Children’s Hospital and Research
    Center Oakland, California —HL-070583
  2. Thomas Jefferson University
    Philadelphia, Pennsylvania —HL-070585
  3. Rho Federal Systems Division, Inc.
    Chapel Hill, North Carolina —HL-070587
  4. University of Texas Southwestern
    Medical Center
    Dallas, Texas —HL-070588
  5. St. Jude Children’s Research Hospital
    Memphis, Tennessee —HL-070590
  6. University of Southern California
    Los Angeles, California —HL-070595
  7. Children’s Hospital of Philadelphia
    Philadelphia, Pennsylvania —HL-070596
  8. Duke University
    Durham, North Carolina —HL-070769
  9. Boston Medical Center
    Boston, Massachusetts —HL-070819
  10. Children’s Hospital Research Center
    Cincinnati, Ohio —HL-070871
  11. Yeshiva University
    New York, New York —HL-070994

Specialized Centers for Cell-Based Therapies for Heart, Lung, and Blood Diseases (U54) Program

The Specialized Centers for Cell-Based Therapies Program, which includes a Data and Coordinating Center, was initiated in FY 2005 to support preclinical and clinical studies for cell-based therapy for heart, lung, and blood diseases and sleep disorders. A key feature of the program is the ability to conduct preclinical studies in the first year or two of the program, in order to meet the requirements for an Investigational New Drug application prior to initiating clinical studies. Clinical studies are expected to be initiated by the beginning of the third year.

Obligations

Fiscal Year 2007—$7,358,849

Current Active Organizations and Grant Numbers

  1. Baylor College of Medicine
    Houston, Texas —HL-081007
  2. EMMES Corporation
    Rockville, Maryland —HL-081021
  3. Johns Hopkins University
    Baltimore, Maryland —HL-081028
  4. Massachusetts General Hospital
    Boston, Massachusetts —HL-081030

Centers for AIDS Research (P30) Program

The NHLBI, along with five other NIH Institutes, contributes to the support of six Centers for AIDS Research that were established to provide a multidisciplinary environment that promotes basic, clinical, behavioral, and translational research activities in the prevention, detection, and treatment of HIV infection and AIDS. Almost half of the patient population comes from minority groups.

Obligations

Fiscal Year 2007—$3,571,285

Current Active Organizations and Grant Numbers

  1. New York University
    School of Medicine
    New York, New York —AI-027742
  2. University of Washington
    Seattle, Washington —AI-027757
  3. University of California, San Francisco
    San Francisco, California —AI-027763
  4. University of Alabama at Birmingham
    Birmingham, Alabama —AI-027767
  5. University of California, Los Angeles
    Los Angeles, California —AI-028697
  6. Baylor University
    Houston, Texas —AI-036211
  7. University of California, San Diego
    La Jolla, California —AI-036214
  8. Case Western Reserve University
    Cleveland, Ohio —AI-036219
  9. University of Massachusetts
    Medical School
    Worcester, Massachusetts —AI-042845
  10. Miriam Hospital
    Providence, Rhode Island —AI-042853
  11. University of Pennsylvania
    Philadelphia, Pennsylvania —AI-045008
  12. Emory University
    Atlanta, Georgia —AI-050409
  13. University of North Carolina
    at Chapel Hill
    Chapel Hill, North Carolina —AI-050410
  14. Yeshiva University
    New York, New York —AI-051519
  15. University of Colorado
    Health Sciences Center
    Denver, Colorado —AI-054907
  16. Vanderbilt University
    Nashville, Tennessee —AI-054999
  17. Harvard Medical School
    Boston, Massachusetts —AI-060354
  18. Duke University
    Durham, North Carolina —AI-064518

Back to Top

« Back

Next »

Fact Book Table of Contents

Skip footer links and go to content